摘要18F-3'-脱氧-3 '-L氟代胸苷(18F-FLT)作为一种增殖示踪剂,利用PET可将细胞增殖活动可视化并进行量化评估,为临床提供了一种非侵入性监测抗肿瘤疗效的检查方法.该文讨论了18F-FLT作为增殖示踪剂的机制,并回顾了目前18F-FLT PET临床前期研究的状况.虽然18F-FLT是一种可以反映细胞增殖活动的示踪剂,但也有很多限制:在大部分病例中,其摄取率显著低于目前临床广泛应用的18F-FDG,而且受化疗方案和肿瘤类型的影响,18F-FLT摄取与细胞增殖活动并不总是一致.

abstracts18F-3'-deoxy-3'-L-fluorothymidine(F-FLT) has been developed as a proliferation tracer in recent years.Imaging and measurement of proliferation with PET could provide clinicians with a non-invasive tool to monitor the response to anticancer treatment.In this review,the basis of 18F-FLT as a proliferation tracer is discussed.And reviewed the current status of 18F-FLT preclinical researches.Although 18F-FLT is a tracer that visualizes cellular proliferation,it also has certain limitations,for example,in comparison with the most widely used PET tracer 18F-FDG,18F-FLT uptake is significant lower in some tumors,and 18F-FLT uptake does not always reflect the tumor cell proliferation rate cause of the different chemothe-rapy regimens.